Citius Pharmaceuticals, Inc. CTXR 深 滬
等待開盤 11-26 09:30:00 美东时间
1.22
+0.080
+7.02%
華盛通- 最 高1.24
- 今 開1.175
- 成交量 77.83万股
- 最 低 1.13
- 昨 收 1.14
- 總市值 1363.29万
- 52周最高 5.95
- 市盈率 靜 --
- 換手率 6.97%
- 52周最低 0.65
- 委 比 95.73%
- 總股本 1117.45万
- 歷史最高 137.25
- 量 比 1.20
- 振 幅 9.65%
- 歷史最低 0.65
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Collaborates With Verix To Further Leverage Tovana Platform To Support Anticipated Q4 2025 U.S. Commercialization Of FDA Approved LYMPHIR For CTCL Treatment
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD, N.J., Nov. 21, 2025 /PRNewswire/
11-21 21:41
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
11-13 01:05
Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On October ...
10-24 05:29
Citius Pharmaceuticals Secures $6M in Stock Offering
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On October 20, 2025...
10-22 05:00
Citius Oncology Announced It Has Finalized An Exclusive Agreement With EVERSANA To Support The Q4 2025 U.S. Commercialization Of LYMPHIR
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapyCRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius
10-16 20:52
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
Citius Oncology To Raise $9M In Registered Direct Offering Of 5.14M Shares At $1.75 Each, Plus Warrants For 5.14M Shares Exercisable At $1.84
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and
09-09 20:47
Citius Oncology prices $9 million offering; shares down over 5%
Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), announced on Tuesday that it has entered into a securities purchase agreement with a single inst...
09-09 20:42
Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targeting and engagementCRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc.
08-22 20:49
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
